Alvaro Lopez, MD
Infectious Disease · Tucker, GANPI 1861440216
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,590 of the $93,390 with a category attached, or 70.2%. Gilead accounts for 82.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $31,057 and has fallen 55.0% since, to $13,960 in 2025. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $167.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$77K
- Merck$5K
- Janssen Products, LP$4K
- Theratechnologies Inc.$2K
- Viiv Healthcare Company$2K
- AbbVie$600
- plus $4K from 21 others
What the payments were for
- Consulting fees$7,6808%
- Speaking & faculty fees$65,59070%
- Travel & lodging$7,6358%
- Food & beverage$11,66712%
- Education$8181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 234 | $77,035 |
| Merck | 48 | $4,761 |
| Janssen Products, LP | 9 | $3,643 |
| Theratechnologies Inc. | 15 | $1,880 |
| Viiv Healthcare Company | 80 | $1,577 |
| AbbVie(2 entities) | 25 | $600 |
| Astellas Pharma US Inc | 13 | $569 |
| Cipla USA Inc. | 1 | $515 |
| Insmed, Inc. | 16 | $509 |
| Shionogi Inc | 20 | $485 |
| Johnson & Johnson | 29 | $328 |
| Melinta Therapeutics, LLC | 19 | $326 |
| La Jolla Pharmaceutical Company | 10 | $218 |
| Paratek Pharmaceuticals, Inc. | 10 | $210 |
| Pfizer | 7 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $131 |
| Smith+Nephew | 1 | $117 |
| Aimmune Therapeutics, Inc. | 3 | $64 |
| Grifols USA, LLC | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $41 |
| Biomerieux Inc | 1 | $40 |
| EMD Serono, Inc. | 2 | $37 |
| CSL Behring | 1 | $32 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $25 |
| Napo Pharmaceuticals Inc | 2 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$45,081
- Symtuza$3,370
- Sunlenca$1,730
- TROGARZO$1,651
- ZEMDRI (PLAZOMICIN)$515
- CABENUVA$125
- Grafix PL PRIME$117
- Stravix$117
- Descovy$112
- Mavyret$104
How this compares
$93,390 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 194 | $790,375 |
| DescovyEmtricitabine/Tenofov Alafenam | 168 | $365,055 |
| IsentressRaltegravir Potassium | 109 | $225,755 |
| TivicayDolutegravir Sodium | 83 | $189,707 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 37 | $167,891 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 31 | $133,677 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 23 | $124,890 |
| PrezcobixDarunavir/Cobicistat | 42 | $108,607 |
| JulucaDolutegravir/Rilpivirine | 30 | $104,549 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $70,154 |
| PifeltroDoravirine | 20 | $39,899 |
| PrezistaDarunavir | 15 | $35,726 |
| Darunavir | 65 | $29,262 |
| EvotazAtazanavir Sulfate/Cobicistat | 18 | $27,927 |
| Etravirine | 13 | $13,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $77,035 | $1,323,322399 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Juluca, Dovato | $1,577 | $498,087168 claims |
| MerckIsentress, Pifeltro | $4,761 | $265,654129 claims |
| Janssen Products, LPSymtuza | $3,643 | $124,89023 claims |
| Johnson & JohnsonPrezcobix | $328 | $108,60742 claims |
| PfizerDilantin | $136 | $57714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Tucker
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jeffrey StephensMacon$356K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Cheryl NewmanAugusta$128K
- Colleen KraftAtlanta$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.